Sun Pharma Ka Profit Badha! India Sales Aur Innovation Ne Machaya Dhoom!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Sun Pharma Ka Profit Badha! India Sales Aur Innovation Ne Machaya Dhoom!
Overview

Arre Sun Pharma ke liye toh khushkhabri hai! Unka Q4 profit gaya **26%** upar, pohanch gaya **₹2,714 crore** pe. India mein sales **14.8%** badhi hai aur ab revenue ka **33%** wahi se aa raha hai. Board ne **₹5** ka final dividend bhi recommend kiya hai. Global innovative medicines bhi mast chal rahe hain.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Sun Pharma ne FY26 ke liye Q4 ke results announce kiye hain, aur numbers dekhne layak hain! Consolidated net profit 26.2% saal-dar-saal badhkar ₹2,714 crore ho gaya hai. Iski sabse badi wajah hai India mein badhti hui sales aur unke innovative medicines ka badhta hua portfolio.

India Business Ne Kiya Kamaal

India mein company ki formulations business ne toh record tod diya! January-March quarter mein sales 14.8% badhi hai, jo ₹4,835.9 crore ho gayi. Isse Sun Pharma Indian pharma market mein aur bhi strong ho gaya hai, market share 8.1% se 8.4% ho gaya. Company ne quarter mein 11 naye products launch kiye hain, aur poore saal mein 37.

Innovative Medicines Ki Dhoom

Global level par bhi innovative medicines ka segment achha perform kar raha hai. Sales 20.1% badhkar $354 million ho gayi hai, jo company ke total revenue ka 22.2% hai. Haan, US market mein sales thoda sa 1.1% gir kar $459 million ho gayi, generic sales kam hone ki wajah se. Par US market ab bhi 28.8% quarterly sales contribute karta hai.

Financials Aur Dividend

Total revenue 13.6% badhkar ₹14,559.8 crore ho gaya hai. Board ne ₹5 per equity share ka final dividend recommend kiya hai. Iske alawa, interim dividend milakar FY26 ke liye total dividend ₹16 per share hi hai, jo pichle saal ke barabar hai.

EBITDA 6.4% badhkar ₹3,954.2 crore raha, jiska margin 27.1% hai. Company ne R&D mein ₹975.7 crore invest kiye hain, jo sales ka 6.7% hai. Poore FY26 mein Sun Pharma ki overall sales 11.9% badhi hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.